Tag:
Prevnar
Latest Headlines
Latest Headlines
Pfizer targets miniblockbuster prospects as Lipitor patent expires
Pfizer ( $PFE ) has been gearing up for the expiration of Lipitor's patent for years, and with the big day finally upon us, analysts and industry watchers are weighing in on the R&D course that the
FDA panel favors Pfizer's Prevnar 13 for expanded use
An FDA advisory panel backed Pfizer's ( $PFE ) Prevnar 13 vaccine for use in adults age 50 and older to stave off pneumonia, meningitis, and other pneumococcal infections. The committee voted 14-1 in
FDA staffers back Pfizer's Prevnar vax for adults
Will Pfizer ( $PFE ) succeed at broadening use of its star vaccine? A report from FDA reviewers suggest it might. In a pre-advisory committee review, agency staffers said the Prevnar 13 vaccine was
To pump up Prevenar, Pfizer looks to rural China
Like any country, China isn't one market, but many. Strategies for capturing share and growing sales in cities won't necessarily work in rural areas. And to grow as much as drugmakers want to in
Pfizer's U.S. sales drop, emerging markets grow
Emerging markets sales helped boost Pfizer's third-quarter profits--and the $1.3 billion gain on its sale of Capsugel didn't hurt, either. The U.S.-based drugmaker beat analyst expectations for sales
Pfizer, Shanghai expand Chinese collaboration
Pfizer ( $PFE ) has taken its relationship with China's Shanghai Pharmaceutical to a new level. Currently cooperating on Pfizer's Prevenar pneumococcal vaccine, the two companies plan to beef up those
Pfizer's Prevnar and Sanofi's ActHIB cleared for Japanese market
After nearly three weeks of suspended vaccinations, Japan has cleared the path for Sanofi-Aventis' ActHIB and Pfizer's Prevnar--marketed as Prevenar--to return to the Japanese market as soon as April
Japan lets Pfizer, Sanofi resume shot sales
Japan has lifted the suspension on two childhood vaccines from Pfizer and Sanofi-Aventis. Regulators said the companies can start selling their Prevnar and ActHIB shots again after a safety probe
Japan finds no vaccine link to child deaths
Japanese experts didn't identify a clear link between two childhood vaccines and the deaths of four children who received them. That's the good news for Pfizer's ( $PFE ) Prevenar--known as Prevnar in
Vaccine gives dangerous pneumococcus strains an opening
When a vaccine that guards against the most common causes of pneumococcal disease comes to the market, it's simultaneously creating fresh opportunities for strains not covered in the shot, scientists
